ArticleAACE endocrinology and diabetes
Inhaled Insulin Dosing in a Randomized Trial in Adults With Type 1 Diabetes.
Article in AACE endocrinology and diabetes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Technosphere insulin (TI) is an ultrarapid-acting inhaled insulin available in 4, 8, and 12 U cartridges. The U.S. Prescribing Information recommends converting subcutaneous rapid-acting insulin analogs (RAAs) to TI by rounding up to the nearest 4-U increment. This study aimed to evaluate TI dosing patterns after initiating therapy at a higher conversion dose than in the U.S. Prescribing Information and characterize subsequent titration needs. Methods: In a multicenter, randomized trial, adults with type 1 diabetes were assigned to TI plus insulin degludec or usual care. TI was initiated at a 2:1 TI-to-RAA unit conversion, rounded down to the nearest cartridge and titrated to glycemic targets. Dosing data were collected at baseline, 17 weeks, and 30 weeks. Results: Across participants randomized to TI with no missing dosing data for 30 weeks ( Conclusion: Most participants who initiated TI at a higher conversion dose still required additional TI uptitration for glucose management. This study highlights the need for higher TI unit dosing requirements in clinical practice to support individualized titration to reach glycemic goals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.